3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
350
Stomach Neoplasms
31
Neoplasm Metastasis
30
Breast Neoplasms, Male
25
Neoplasms
16
Inflammatory Breast Neoplasms
12
Brain Neoplasms
12
Carcinoma, Non-Small-Cell Lung
10
Esophageal Neoplasms
7
Prostatic Neoplasms
6
Pancreatic Neoplasms
6
Urinary Bladder Neoplasms
5
Rectal Neoplasms
5
Adenocarcinoma
5
Sarcoma
4
Lung Neoplasms
4
HER2-positive Breast Cancer
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Colonic Neoplasms
4
Unspecified Adult Solid Tumor, Protocol Specific
3
Triple Negative Breast Neoplasms
3
Salivary Gland Neoplasms
3
Head and Neck Neoplasms
3
HER2 Positive Breast Cancer
3
Cardiotoxicity
3
Carcinoma, Renal Cell
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Hepatocellular
3
Carcinoma, Ductal, Breast
3
Interventions
pertuzumab
1
pazopanib
1
daratumumab
1
Trastuzumab
1
Surgical Procedures, Operative
1
Sunitinib
1
Sorafenib
1
Risk Assessment
1
Radiotherapy
1
Injections, Subcutaneous
1
Focus Groups
1
Bandages, Hydrocolloid
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Patient Preference
×
Trastuzumab
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts